BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abou-El-Enein M, Bauer G, Medcalf N, Volk HD, Reinke P. Putting a price tag on novel autologous cellular therapies. Cytotherapy. 2016;18:1056-1061. [PMID: 27288308 DOI: 10.1016/j.jcyt.2016.05.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Davies BM, Smith J, Rikabi S, Wartolowska K, Morrey M, French A, MacLaren R, Williams D, Bure K, Pinedo-Villanueva R. A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies. J Tissue Eng. 2017;8:2041731417724413. [PMID: 28835816 DOI: 10.1177/2041731417724413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Elsanhoury A, Sanzenbacher R, Reinke P, Abou-El-Enein M. Accelerating Patients' Access to Advanced Therapies in the EU. Mol Ther Methods Clin Dev 2017;7:15-9. [PMID: 28971109 DOI: 10.1016/j.omtm.2017.08.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
3 Schwartz EN, Edmondson CP. Medical and Metabolic Considerations in Athletes With Stress Fractures. Baxter's the Foot and Ankle in Sport. Elsevier; 2020. pp. 30-94. [DOI: 10.1016/b978-0-323-54942-4.00004-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Migliori E, Chang M, Muranski P. Restoring antiviral immunity with adoptive transfer of ex-vivo generated T cells: . Current Opinion in Hematology 2018;25:486-93. [DOI: 10.1097/moh.0000000000000461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Bandeiras C, Cabral JM, Finkelstein SN, Ferreira FC. Modeling biological and economic uncertainty on cell therapy manufacturing: the choice of culture media supplementation. Regen Med 2018;13:917-33. [PMID: 30488770 DOI: 10.2217/rme-2018-0034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Abou-El-Enein M, Duda GN, Gruskin EA, Grainger DW. Strategies for Derisking Translational Processes for Biomedical Technologies. Trends Biotechnol 2017;35:100-8. [PMID: 27499276 DOI: 10.1016/j.tibtech.2016.07.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
7 van Overbeeke E, Michelsen S, Toumi M, Stevens H, Trusheim M, Huys I, Simoens S. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today 2021;26:399-415. [PMID: 33242695 DOI: 10.1016/j.drudis.2020.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tran R, Myers DR, Denning G, Shields JE, Lytle AM, Alrowais H, Qiu Y, Sakurai Y, Li WC, Brand O, Le Doux JM, Spencer HT, Doering CB, Lam WA. Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency. Mol Ther 2017;25:2372-82. [PMID: 28780274 DOI: 10.1016/j.ymthe.2017.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
9 Hoogduijn MJ, Issa F, Casiraghi F, Reinders MEJ. Cellular therapies in organ transplantation. Transpl Int 2021;34:233-44. [PMID: 33207013 DOI: 10.1111/tri.13789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res 2018;7:15-28. [PMID: 29144165 DOI: 10.2217/cer-2017-0068] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
11 Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell. 2016;19:293-297. [PMID: 27588746 DOI: 10.1016/j.stem.2016.08.012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 18.3] [Reference Citation Analysis]
12 MacLeod DT, Antony J, Martin AJ, Moser RJ, Hekele A, Wetzel KJ, Brown AE, Triggiano MA, Hux JA, Pham CD, Bartsevich VV, Turner CA, Lape J, Kirkland S, Beard CW, Smith J, Hirsch ML, Nicholson MG, Jantz D, McCreedy B. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells. Mol Ther 2017;25:949-61. [PMID: 28237835 DOI: 10.1016/j.ymthe.2017.02.005] [Cited by in Crossref: 109] [Cited by in F6Publishing: 87] [Article Influence: 27.3] [Reference Citation Analysis]
13 Fritsche E, Volk H, Reinke P, Abou-el-enein M. Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends in Biotechnology 2020;38:1099-112. [DOI: 10.1016/j.tibtech.2019.12.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 26.0] [Reference Citation Analysis]
14 Mcphail MJ, Janus JR, Lott DG. Advances in regenerative medicine for otolaryngology/head and neck surgery. BMJ. [DOI: 10.1136/bmj.m718] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Quinn C, Young C, Thomas J, Trusheim M. Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System. Value in Health 2019;22:621-6. [DOI: 10.1016/j.jval.2019.03.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 10.5] [Reference Citation Analysis]
16 Bailey SR, Maus MV. Gene editing for immune cell therapies. Nat Biotechnol 2019;37:1425-34. [DOI: 10.1038/s41587-019-0137-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 51] [Article Influence: 37.5] [Reference Citation Analysis]
17 Bauer G, Abou-El-Enein M, Kent A, Poole B, Forte M. The path to successful commercialization of cell and gene therapies: empowering patient advocates. Cytotherapy 2017;19:293-8. [PMID: 27956199 DOI: 10.1016/j.jcyt.2016.10.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Morrow D, Ussi A, Migliaccio G. Addressing Pressing Needs in the Development of Advanced Therapies. Front Bioeng Biotechnol 2017;5:55. [PMID: 28993805 DOI: 10.3389/fbioe.2017.00055] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
19 Teraa M, Gremmels H, Wijnand JGJ, Verhaar MC. Cell Therapy for Chronic Limb-Threatening Ischemia: Current Evidence and Future Directions. Stem Cells Transl Med 2018;7:842-6. [PMID: 30070050 DOI: 10.1002/sctm.18-0025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Vollrath I, Mathaes R, Sediq AS, Jere D, Jörg S, Huwyler J, Mahler H. Subvisible Particulate Contamination in Cell Therapy Products—Can We Distinguish? Journal of Pharmaceutical Sciences 2020;109:216-9. [DOI: 10.1016/j.xphs.2019.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]